Methylisoeugenol (1,2-dimethoxy-4-propenylbenzene, 1) is a minor constituent of essential oils, naturally occurring as a mixture of cis/trans isomers. 1 is a U.S. Food and Drug Administration-approved food additive and has been given "Generally Recognized as Safe" status. Previously, metabolism of 1 has been studied in the rat, revealing mainly nontoxic cinnamoyl derivatives as major metabolites. However, data concerning the possible formation of reactive intermediary metabolites are not available to date. In this study, the oxidative metabolism of 1 was studied using liver microsomes of rat [not induced, rat liver microsomes (RLM); Aroclor1254 induced RLM (ARLM)], bovine, and human (pooled from 150 donors) origin. Incubations of these microsomes with 1 provided phase I metabolites that were separated by high-performance liquid chromatography (HPLC) and identified by NMR and UV-visible spectroscopy and/or liquid chromatography-mass spectrometry. Identity was confirmed by comparison with 1 H NMR spectra of synthesized reference compounds. Formation of metabolites was quantified by HPLC/UV using dihydromethyleugenol (10) synthesized as the internal standard. From incubations of ARLM with 1, seven metabolites could be detected, with 3-hydroxymethylisoeugenol (2), isoeugenol and isochavibetol (3 ؉ 4), and 6-hydroxymethylisoeugenol (5) being the main metabolites. Secondary metabolites derived from 1 were identified as the ␣,␤-unsaturated aldehyde 3-oxomethylisoeugenol (6) and 1,2-dihydroxy-dihydromethylisoeugenol (7). We were surprised to find that formation of allylic 6-hydroxymethyleugenol (8) was observed starting at approximately 30 min after the beginning of incubations with ARLM. HLM did not form ring-hydroxylated metabolites but were most active in the formation of 6 and 7. ARLM incubations displayed the highest turnover rate and broadest metabolic pattern, presumably resulting from an increased expression of cytochrome P450 enzymes. In conclusion, we present a virtually complete pattern of nonconjugated microsomal metabolites of 1 comprising reactive metabolites and suggest the formation of reactive intermediates that need more investigation with respect to their possible adverse properties.
Introduction
Methylisoeugenol (1,2-dimethoxy-4-propenylbenzene, 1; see Fig. 5 ) is an alkenylbenzene naturally occurring as a mixture of cis/trans isomers in essential oils of Asarum arifolium, Cymbopogon javanensis, and in nearly 60 other essential oils (Opdyke, 1975) . It is used in perfumery as an ingredient having a clove-carnation odor and is applied as an additive to foods in the parts-per-million range.
1 was classified as "Generally Recognized as Safe" by the Flavor and Extract Manufacture Association in 1965 and is approved by the U.S. Food and Drug Administration (2010) for food use. The acute oral LD 50 in rats was reported to be 1.5 and 2.5 g/kg b.wt. (Opdyke, 1975) . Adverse effects have not been seen in a feeding study with rats receiving 300 mg/kg b.wt. per day (Purchase et al., 1992) . Overall, 1 has been claimed to be nongenotoxic (Hasheminejad and Caldwell, 1994) , although definite data were missing.
When applied at full strength, 1 was irritating to skin (rabbit), but concentrations up to 8% in petrolatum did not produce irritations on human subjects. When an equal concentration was used, 1 did not cause sensitization in a maximization test on human volunteers (Opdyke, 1975) . However, sensitization was positive in a local lymph node assay on mice (Research Institute for Fragrance Materials, www.rifm.org).
The major metabolic pathway of 1 in the rat was found to be the oxidative transformation of the propenyl side chain leading to hydroxy-and/or methoxy-substituted cinnamic and benzoic acids. Other reactions were O-demethylation and oxidation to 3,4-dimethoxyphenylacetic acid and 4-hydroxy-3-methoxyphenylacetone. Epoxidation of the side chain appeared to be a minor metabolic reaction (Solheim and Scheline, 1976) . The metabolites reported in this previous study suggest the formation of reactive intermediates that may lead to hapten formation or may trigger other adverse effects. In our study, we intended to investigate the complete spectrum of metabolites of 1 formed by incubations with liver microsomes of different species.
Materials and Methods
Chemicals. Acetone, CDCl 3 , and dimethyl sulfoxide (DMSO) were purchased from Merck (Darmstadt, Germany). ␤-NADP, glucose 6-phosphate, and glucose-6-phosphate dehydrogenase were obtained from Sigma-Aldrich/ Fluka (Taufenkirchen, Germany). Methanol was obtained in high-performance liquid chromatography (HPLC) gradient grade from J. T. Baker (Griesheim, Germany). Aroclor1254 was originally purchased from Monsanto (St. Louis, MO). 1, isoeugenol (3), methyleugenol (11), and DMSO-d 6 were purchased from Sigma-Aldrich (Steinheim, Germany) at Ͼ98% purity. The purity of the chemicals was checked by HPLC analysis and/or NMR spectroscopy. Metabolites of 1 were synthesized according to the procedures described under Synthesis. The nomenclature of compounds and metabolites follows the numbering indicated in Fig. 5 (Merck, Darmstadt, Germany) . Infrared (IR) spectra were recorded on a JASCO FT/IR-6100 spectrophotometer (Jasco, Gross-Umstadt, Germany). The liquid chromatography-tandem mass spectrometry system consisted of a PerkinElmer liquid chromatography system coupled to an API 2000 Q trap instrument (Applied Biosystems, Foster City, CA). The mass spectrometer was operated using an atmospheric pressure chemical ionization source in the positive ion mode. Acquisition and data processing were done with Analyst software, version 1.4 (Applied Biosystems). The instrumental settings used for the liquid chromatography/tandem mass spectrometry analysis were as follows: ion source temperature 490°C; declustering potential 19 V; needle current 5 V; focusing potential 364 V; entrance potential 8.5 V; curtain gas 19; ion source gas 48; and turbo gas 52 (the latter three are given in arbitrary units from Analyst software). Analytical HPLC was carried out using an Agilent 1100 HPLC system equipped with an autosampler (series G1329A), a quadruple pumping system (series G1311A), a diode array spectrophotometer (DAD; series G1315A), and a column heater (series G1316A) (Agilent, Waldbronn, Germany). HPLC and liquid chromatography-tandem mass spectrometry separations were performed using a C18 column [Hibar (5 m, 4 ϫ 125 mm) and LiChrosorb; Merck, Darmstadt, Germany]. The mobile phase system consisted of buffer A (10 mM NH 4 OAc in water) and buffer B (pure methanol). Separation was achieved using a 30-min linear gradient to 70% buffer B from initial conditions of 10% buffer B following a 5-min period with constant eluent consistency of 70% buffer B with a total analysis time of 38 min per sample at a flow rate of 1 ml/min. The column temperature was kept constant at 35°C. Detection wavelengths were 230, 261, and 280 nm with a reference wavelength of 340 nm each and the detection wavelength of 340 nm with 450 nm as reference wavelength. Injection volumes were 50 l each. Preparative HPLC was performed with an Agilent 1200 series system comprising two preparative pumps (series G1361A), an automatic fraction collector (series G1364B), and a multiwave detector (series G1315A). Injection was achieved over a manual valve with sample loops of 2-ml (incubations) or 10-ml (synthesis) volume. As solid phase, RP18 (Reprosil 100, 5 m, 250 ϫ 20 mm; Dr. Maisch GmbH, Ammerbuch-Entringen, Germany) was used.
Quantification. For quantification of the formed microsomal metabolites, the synthesized reference compounds were measured at concentrations of 1, 10, 50, 100, 500, and 1000 M in methanol with the HPLC gradient described under Analytical Methods. Injection volumes were 50 l each. Peak areas (area under the curve) detected at four different wavelengths ( ϭ 230, 261, 280, and 340 nm) were plotted versus concentration. Metabolite concentrations were calculated with the slope of the linear regression (R 2 Ͼ 0.99 for each compound) at the most sensitive wavelength.
Internal Standard. As internal standard, dihydromethyleugenol (1,2-dimethoxy-4-propylbenzene, 10) was synthesized according to the method given under Synthesis. Its retention time was 31 min, a time when no metabolites were found to elute.
Microsomes. All animal experiments (rats) were performed according to National Animal Welfare Regulations after authorization by the local authorities (Struktur-und Genehmigungsbehörde Rheinland-Pfalz). Male Wistar rats were purchased from Charles River (Sulzbach, Germany). Animals were kept under a 12-h light/dark cycle and received water and commercial laboratory chow ad libitum. For inducing experiments, rats (b.wt. 180 -250 g) were given a single dose of 500 mg/kg b.wt. Aroclor1254 i.p. from a stock solution of 200 mg/ml Aroclor1254 dissolved in corn oil. Five days after treatment the animals were sacrificed. Aroclor1254-treated rat (ARLM), noninduced rat (RLM), and bovine liver microsomes (BLM) were prepared from the liver of freshly sacrificed/slaughtered animals as described for rat liver by Melancon et al. (1985) . Bovine livers were from 1.5-to 2-year-old female German Black Pied cattle (dairy cattle) and were obtained from a local slaughterhouse. Human liver microsomes (HLM) were purchased from BD Bioscience (Heidelberg, Germany) from a pool derived from 150 gender-mixed donors. Protein was measured photometrically using the method of Bradford (1976) . Total cytochrome P450 (P450) contents were measured according to the method of Omura and Sato (1962) .
Incubations. Incubations of microsomes (2 mg of microsomal protein/ml) were performed with 0.1, 0.5, or 2.5 mM substrate dissolved in DMSO (final concentration 5%) with a NADPH-regenerating system consisting of 1 mM NADPH, 0.5 units glucose-6-phosphate dehydrogenase, 5 mM glucose 6-phosphate, 3 mM magnesium chloride, and 50 mM phosphate buffer, pH 7.4. Incubations were carried out in various volumes (from 1 to 100 ml for preparative uses) and were gently shaken in an incubator (TH-30; Carl Roth, Karlsruhe, Germany) at 37°C. After preincubation with substrate for 5 min at 37°C, the NADPH-generating system was added and the mixture was incubated for up to 24 h. Control incubations were carried out with heat-inactivated microsomes and with intact microsomes but without the NADPH-regenerating system, respectively. Incubations and time-course measurements were done in triplicate as independent experiments. The high concentration of DMSO (5%) was applied to improve solubility of the substrate, in particular of isolated metabolites. Although DMSO is known to act as a P450 inhibitor, concentrations of metabolites in control incubations of 1 using 0.5% DMSO were found not to be significantly different (data not shown).
Sample Preparation. After incubation, samples were diluted with equal volumes of a ice-cold solution (Ϫ20°C) of acetone containing 0.1 or 0.5 mM 10 as an internal standard. Samples were cooled for 20 min on ice. The mixtures were shaken intensely, and the precipitated protein was removed by centrifugation at 13,000g for 5 min. For time-course measurements, the supernatants were used directly for HPLC analysis. The supernatants of single incubations were extracted five times with an equal volume of ethyl acetate (EtOAc). The solvent of the combined organic phases was removed, and the residue was taken up in a defined volume of methanol before further analysis.
Synthesis. 3Ј-Hydroxymethylisoeugenol (2) was prepared according to the method of Solheim and Scheline (1976) using 1Ј-hydroxymethyleugenol (9) (E)-6-Hydroxymethylisoeugenol (5) was synthesized according to Shulgin (1965) by isomerization of 6-hydroxymethyleugenol (8). Under argon atmosphere, a mixture of 8 (4.5 g, 23.2 mmol) and potassium hydroxide (11.2 g; 0.20 mol) in dried ethanol (5 ml) was stirred at 140 -150°C for 7 days. Reaction control was accomplished by analytical HPLC. Additional KOH (11.2 g; 0.20 mol) was added after 48 and 96 h, each. The reaction was stopped after 7 days because no further conversion was observed. Five hundred milliliters of water were added, and the mixture was acidified with dilute sulfuric acid and extracted with ethyl acetate (four times, 150 ml each). The combined organic layers were dried (MgSO 4 ) and the solvent was evaporated in vacuo. The crude product (4.2 g) was purified by column chromatography using silica gel and ethyl acetate/hexane (1:2). Crystallization from ethyl acetate/pentane yielded the pure trans-isomer 5 (2. 
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Hz, J ϭ 1.4 Hz); 6.83 (s, 1H, H2); 9.05 (s; 1H, OH);
13 C{ 1 H}-NMR (DMSOd 6 , 25°C, 100 MHz) ␦ 18. 6, 55.3; 56.2; 100.9; 110; 115.5; 121.9; 125.6; 142; 148.2; 148.6 ppm; IR (KBr): 3405, 3040, 3009, 2995 , 2956 , 2932 , 2848 , 1615 , 1524 , 1454 , 1419 , 1375 , 1297 , 1266 , 1204 , 1115 , 1033 ; t R (HPLC-UV; 261 nm, 500 M) ϭ 21.5 min; UV/Vis (HPLC-DAD): max (absolute absorbance in mAU) ϭ 215 (1100), 257 (700), 315 (350) nm.
(E)-3Ј-Oxomethylisoeugenol (6) was synthesized according to the method of Bürgi et al. (1993) 3437, 2929, 2838, 1667, 1619, 1597, 1512, 1469, 1426, 1400, 1273, 1225, 1165, 1129,1037, 1017, 984, 794, 581 cm Ϫ1 ; t R (HPLC-UV) ϭ 19 min (261 nm; 1 mM); UV/Vis (HPLC-DAD): max (absolute absorbance in mAU) ϭ 230 (2600), 240 (3000), 300 (3000), 360 (2750) nm.
For synthesis of 1Ј,2Ј-dihydroxymethylisoeugenol (7), a solution of 1 (1 g, 5.61 mmol) in dichloromethane (15 ml) was added to a mixture (20 ml 1:1, v/v) of a solution of saturated sodium bicarbonate and a solution of saturated ammonium chloride. A solution of meta-chloroperbenzoic acid (70%, 1.45 g, 5.88 mmol) in dichloromethane (10 ml) was added dropwise. The mixture was vigorously stirred for 2 h at room temperature. The organic layer was separated, and the aqueous layer was extracted with dichloromethane three times. The combined organic phases were washed three times with water, dried over MgSO 4 , and the solvent was removed in vacuo to yield 1-(3,4-dimethoxyphenyl)-1-hydroxypropane-2-yl-3-chlorobenzoate ( 3515, 3069, 2972, 2936, 2908, 2837, 1721, 1606, 1594, 1518, 1465, 1422, 1346, 1321, 1256, 1161, 1139, 1087, 1073, 1027, 978, 897, 866, 849, 809, 793, 749, 737, 702, 674, 665, 645 cm Ϫ1 . This intermediate was used without further purification. To 1.83 g (5.23 mmol) of this intermediate in methanol (30 ml), sodium hydroxide (1.56 g, 39 mmol) in methanol (10 ml) was added. The solution was refluxed for 1 h until no starting material was detectable by thin-layer chromatography. After cooling to room temperature, the solution was acidified with 1 N HCl and adjusted to pH 10 using a saturated solution of ammonium bicarbonate. The aqueous layer was extracted three times with EtOAc (30 ml). The combined organic layers were washed with brine and water, dried (MgSO 4 ), and the solvent was evaporated in vacuo. Yield: 1 g (4.74 mmol, 91%, white solid). Analysis: R f ϭ 0.14 (EtOAc/hexane 1:3) 3274, 2964, 2930, 2834, 1606, 1594, 1520, 1460, 1420, 1373, 1343, 1260, 1239, 1160, 1146, 1079, 1057, 1025, 910, 819, 789, 764, 644, 618, 598, 543 3, 55.5; 56.5; 101; 114.8; 114.9; 116.6; 137.6; 141.6; 147.8; 148.8 ppm; IR (neat): 3445, 3077, 3002, 2937 IR (neat): 3445, 3077, 3002, , 2911 IR (neat): 3445, 3077, 3002, , 2836 IR (neat): 3445, 3077, 3002, , 1637 IR (neat): 3445, 3077, 3002, , 1617 IR (neat): 3445, 3077, 3002, , 1523 IR (neat): 3445, 3077, 3002, , 1465 IR (neat): 3445, 3077, 3002, , 1451 IR (neat): 3445, 3077, 3002, , 1415 IR (neat): 3445, 3077, 3002, , 1360 IR (neat): 3445, 3077, 3002, , 1295 IR (neat): 3445, 3077, 3002, , 1238 IR (neat): 3445, 3077, 3002, , 1203 9; 56.1; 73.7; 110.7; 112.2; 113.5; 118.8; 137.4; 142.7; 148.3; 149.1 ppm; IR (neat): 3504, 3583, 3504, 3078, 3002, 2936 IR (neat): 3504, 3583, 3504, 3078, 3002, , 2836 IR (neat): 3504, 3583, 3504, 3078, 3002, , 1735 IR (neat): 3504, 3583, 3504, 3078, 3002, , 1640 IR (neat): 3504, 3583, 3504, 3078, 3002, , 1594 IR (neat): 3504, 3583, 3504, 3078, 3002, , 1515 IR (neat): 3504, 3583, 3504, 3078, 3002, , 1464 IR (neat): 3504, 3583, 3504, 3078, 3002, , 1418 IR (neat): 3504, 3583, 3504, 3078, 3002, , 1374 IR (neat): 3504, 3583, 3504, 3078, 3002, , 1339 IR (neat): 3504, 3583, 3504, 3078, 3002, , 1262 IR (neat): 3504, 3583, 3504, 3078, 3002, , 1234 IR (neat): 3504, 3583, 3504, 3078, 3002, , 1186 IR (neat): 3504, 3583, 3504, 3078, 3002, , 1155 IR (neat): 3504, 3583, 3504, 3078, 3002, , 1139 IR (neat): 3504, 3583, 3504, 3078, 3002, , 1028 ; t R (HPLC-UV) ϭ 16.4 min (280 nm; 500 M); UV/Vis (HPLC-DAD): max (absolute absorbance in mAU) ϭ 233 (280), 278 (100) nm.
10 was prepared in a hydrogenation apparatus, 289 mg of Pd/C (10%) were added to a solution of 11 (3 g; 16.8 mmol) in ethanol (30 ml). The suspension was stirred vigorously under slight excess pressure at room temperature until 381 cm 3 of hydrogen (17 mmol) was taken up. The charcoal was filtered off, and the solvent was removed in vacuo. Yield: 1.09 g (6.60 mmol, 99%, colorless oil). Analysis: R f ϭ 0.57 (EtOAc/hexane 1:4); 1 H NMR (DMSO-d 6 , 400 MHz) ␦ 0.86 (t, 3H, H3Ј, J ϭ 7.5 Hz); 1.54 (sext, 2H, H2Ј, J ϭ 7.5 Hz); 2.46 (t, 2H, H1Ј, J ϭ 7.5 Hz); 3.69 (s, 3H, OCH 3 ); 3.71 (s, 3H, OCH 3 ); 6.66 (dd, 1H, H6, J ϭ 8.2 Hz, J ϭ 1.7 Hz); 6.75 (d, 1H, H2, J ϭ 1.7 Hz); 6.81 (d, 1H, H5; J ϭ 8.2 Hz); IR (KBr): 2997, 2957, 2932, 2870, 2834, 1607, 1590, 1516, 1465, 1416, 1377, 1341, 1262, 1236, 1191, 1156, 1141, 1092, 1031, 846, 806, 764, 666 cm Ϫ1 ; t R (HPLC-UV) ϭ 31 min (280 nm; 500 M); UV/Vis (HPLC-DAD): max (absolute absorbance in mAU) ϭ 230 (270), 280 (100) nm.
2Ј,3Ј-Dihydroxymethyleugenol (13) was synthesized with 2Ј,3Ј-epoxymethyleugenol (101 mg; 0.52 mmol, prepared by the method of Fieser, 1967) . The starting material was mixed with 5 ml of water at 25°C. Solid potassium hydroxide (270 mg, 15.1 mmol) was added, and the mixture was refluxed for 2 h. After cooling to room temperature, 6 N HCl was added up to pH of 5 to 6. The mixture was extracted three times with ethyl acetate, and the combined organic layers were dried (MgSO 4 ), filtered, and concentrated in vacuo to yield 13 as a white solid (76 mg, 0.36 mmol, 69% 3447, 2937, 2841, 1683, 1625, 1596, 1584, 1516, 1457, 1426, 1408, 1340, 1315, 1299, 1263, 1210, 1169, 1141, 1024, 976, 939, 840, 811, 580 cm Ϫ1 ; t R (HPLC-UV) ϭ 6.5 min (280 nm; 0.5 mM); UV/Vis (HPLC-DAD): max (absolute absorbance in mAU) ϭ 215 (600), 230 (540), 285 (590), 312 (580) nm.
Results
Human, bovine, and rat (Aroclor1254-induced and noninduced) liver microsomes were incubated with 1 in the presence of a NADPHgenerating system to generate metabolites formed by metabolic phase I reactions. Incubations without the NADPH-generating system did not produce metabolites in detectable amounts (data not shown). Relatively high concentrations (100 and 500 M) of 1 were used with incubations to ensure detection of lesser-formed metabolites.
After workup, supernatants of the incubations were analyzed by reversed-phase HPLC/DAD. Peaks of metabolites were separated and examined using HPLC/MS and 1 H NMR spectroscopy. Formation of the main metabolites and a decrease in substrate concentration were monitored in microsomal incubations of different species and different concentrations. The total content of P450 enzymes in these incubations was determined to be 1.67 (ARLM), 0.33 (RLM), 0.88 (BLM), and 0.35 (HLM) nmol/mg protein.
Oxidative Metabolism of 1. Incubations of ARLM with 1 produced the widest spectrum of metabolites, with 2 through 8 displaying the largest peak areas at a substrate concentration of 500 M (Fig. 1) . These metabolites were identified by comparison of HPLC retention times and UV spectra to those of synthetic reference compounds, if available.
The favored metabolic steps in ARLM were the hydroxylation of the propenyl side chain leading to 2 and the hydroxylation at position 6 of the aromatic ring leading to 5 and 8. Furthermore, the 1Ј,2Ј-diol 7 was identified. The products of demethylation of one of the methoxy groups were identified as 3 and characterized as isochavibetol (4). Although no reference compound was available for 4, its formation in the incubation mixtures with liver microsomes was tentatively confirmed by analyzing its MS data ([MϩH] ϩ ϭ 165 m/z). Furthermore, its UV spectrum [215 (1200 units), 260 (800 units), 300 (450 units) nm] was identical (data not shown) to the spectrum of 3, as expected. It is interesting to note that 5 could already be detected 10 min after NADPH addition, whereas 8 was first detected 30 min after addition of the NADPH-generating system. This metabolic transformation was only found in incubations with ARLM. However, the concentration of 5 decreased during further incubation; that is, 5 could barely be detected after 24 h of incubation. After 2 h, the formation of 6 became observable as indicated by a "negative" peak. This is due to the used reference wavelength (340 nm) at which 6 exclusively shows a marked absorption. Quantification of this metabolite was achieved using a detection wavelength of 340 nm and a reference wavelength of 450 nm.
In Fig. 2 , the time course of levels of metabolites formed during incubations of 2 (500 M) with liver microsomes of different origins is shown. The remaining substrate 1 and the major metabolites 2 through 7 could be quantified. For clarity of the figures, the concentrations of the metabolites 3, 4, 6, and 7 are shown as sums. The fact that the calculated sum of concentrations of substrate and quantified metabolites was less than 100% points to the formation of further metabolites or reaction products, the amounts of which could not be specified. This difference was found to increase with progressive time of incubation, suggesting the formation of conjugated metabolites and/or of metabolites binding to macromolecules. In ARLM (Fig.  2A) , the strongest decline of 1 over time was observed. The 3Ј-alcohol 2, the ring-hydroxylated products 5 and 8, and the sum of the minor metabolites 3, 4, and 7 almost equally contributed to the overall yield of metabolites. In contrast, the slightly lower yield of metabolites in microsomes from untreated rats (RLM) mainly consisted of 2 (Fig.  2B ) with some minor formation of 3 ϩ 4 and 6 but a lack of 5, 7, and 8. In BLM 2 also dominated, whereas lower amounts of 5, 6, and 7 and of the sum of 3 ؉ 4 were found (Fig. 2C) . In human liver microsomes (Fig. 2D) , a similar picture was obtained with respect to the dominating role of 2. However, in addition to some formation of 3 ϩ 4 and 7, no formation of 5 or 8 could be detected.
In Table 1 , the amounts of metabolites formed in ARLM, RLM, BLM, and HLM are expressed as percentage of the substrate concentration of 1 (at 100 or 500 M starting concentration, respectively) at the start of the incubation. At the lower substrate concentration of 100 M, only levels after 2 h of incubation were monitored because several metabolites were below the limits of detection at earlier time points. In contrast, the metabolic capacity of ARLM was sufficient to lead to an almost complete loss of metabolites after 2 h. Therefore, (3 ϩ 4) 5.8 Ϯ 0.0 6.9 Ϯ 3.5 4.5 Ϯ 0.2 2.7 Ϯ 0.6 1.8 Ϯ 0.2 1.2 Ϯ 0.0 5.0 Ϯ 0.4 3.6 Ϯ 0.3 6-Hydroxymethylisoeugenol (5) 34.5 Ϯ 0.9 15.6 Ϯ 0.9 ND ND 3.3 Ϯ 1.1 7.5 Ϯ 0.2 ND ND 3Ј-Oxomethylisoeugenol (6) 0.3 Ϯ 0.0 0.5 Ϯ 0.2 9.0 Ϯ 1.1 2.1 Ϯ 0.0 2.7 Ϯ 0.7 0.7 0.2 7.0 Ϯ 3.1 3.0 Ϯ 1.1 1Ј,2Ј-Dihydroxymethylisoeugenol (7) 2.8 Ϯ 0.6 3.2 Ϯ 1.1 ND ND 2.2 Ϯ 0.1 2.3 Ϯ 0.1 7.0 Ϯ 1.6 1.0 Ϯ 0.1 6-Hydroxymethyleugenol (8 
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at ASPET Journals on April 20, 2017 dmd.aspetjournals.org Table 1 shows the pattern of metabolites for ARLM at 100 M substrate concentration after only 10 min. At a substrate concentration of 100 M, 5 became the dominating metabolite in ARLM, followed by 2 and the minor metabolites 3, 4, 7, and 8. In RLM, the relative yield of 2 was also decreased at the lower substrate concentration; however, this was not the case in BLM and HLM. In HLM, the decrease in substrate concentration even seemed to slightly enhance the relative formation of 2, whereas formation of 7 was strongly enhanced.
Incubation of Synthesized Metabolites 2 and 5 with Liver Microsomes.
For the elucidation of the metabolic pathways, and for a more precise specification of minor metabolites generated during incubations with 1, ARLM were incubated with compound 2, synthesized as a reference substance. After workup, the supernatants of these incubations were applied to HPLC analysis.
Five secondary metabolites were detected in addition to nonmetabolized substrate (57%) after 3 h (Fig. 3) . The negative peak eluting at 19 min was identified as the aldehyde 6, resulting from microsomal oxidation of the hydroxy group in the 3Ј position. The compound with a t R of 10.5 min showed intense absorption at 280 nm (Fig. 3A) and a weaker absorption at 261 nm (Fig. 3B) , more characteristic for an allyl or saturated side chain attached to the phenyl ring. The peak at a t R of 6.3 min displayed spectroscopic characteristics indicating an ␣,␤-unsaturated oxo compound. According to their retention times and spectral properties, both of these compounds are presumed to be 13 (t R ϭ 10.5 min) and 14 (t R ϭ 6.3 min). In contrast, the compounds with t R values of 11.7 and 12.3 min displayed strong absorbance at 261 nm and weaker absorbance at 280 nm, being characteristic for compounds carrying a 2-propenyl side chain. The retention times point to dihydroxy derivatives of 1 (e.g., bearing one hydroxyl group at the side chain and another at the aromatic ring). However, preparative separation of these secondary metabolites failed, so identification via NMR spectra was not feasible.
Because the formation of 8, representing an allylic compound, during incubation of ARLM with 1 seems to be uncommon, we also investigated the metabolism of synthetic 5. In Fig. 4 , chromatograms of incubation supernatants of HLM with 5 (100 M, 2 h, t R ϭ 21.5 min) are depicted. The concentration of 8 (t R ϭ 20.0 min) continuously increased during the incubation period. At a retention time of 16.3 min, a metabolite was formed displaying a negative peak. The UV spectrum of this compound showed a maximum of absorption at 340 nm, indicative of an ␣,␤-unsaturated oxo compound. The metabolic transformation of 5 leading to 8 was observed for all liver microsomes tested using 100 M starting concentration of 5 with a ranking HLM Ͼ ARLM Ͼ BLM Ͼ RLM (data not shown). However, using higher starting concentrations of 5 (500 M and 1 mM), the formation rate of 5 rapidly decreases (data not shown). 
Discussion
Whereas previous investigations on incubations of liver microsomes treated with 11 as a substrate (Gardner et al., 1997; Smith et al., 2002; Jeurissen et al., 2006) were performed to clarify the formation of the proximate carcinogen 9, no reports dealing with investigations on the metabolism of 1 in liver microsomes are available.
Incubation with microsomes from untreated and Aroclor1254-treated rats and of bovine and human origin revealed the more or less complex pattern of phase-I metabolites depicted in Fig. 5 . As discussed in the following, some of the metabolites shown were not found in all incubations.
The main metabolite in nearly all types of incubations, the 3Ј-hydroxy metabolite 2 is considered as a nonmutagenic product. However, our study revealed that it can be converted into the ␣,␤-unsaturated aldehyde 6 and is probably capable of forming Michael adducts. Such reactions with, for example, amino acids and proteins, possibly play a role in liver toxicity and hapten formation. 6 is likely to be metabolized further to the corresponding carboxylic acid 14.
In contrast to incubations with methyleugenol, whereupon isomerization of the side chain and hydroxylation in the 3Ј position was found (A. T. Cartus, unpublished data), the corresponding isomerization of 2 resulting in the formation of 9 was not observed in our experiments. This is in agreement with previous investigations that showed a lack of genotoxicity of 1 in rat hepatocytes in culture (Hasheminejad and Caldwell, 1994) . Starting with a propen-1-yl side chain, the formation of an allylic cation obviously does not seem to be energetically advantageous. However, as early as 30 min after starting the ARLM incubation with 1, the formation of 8 was observed, suggesting that the hydroxy group adjacent to the propenyl side chain may facilitate isomerization to the corresponding allyl compound. Similar findings have been reported for the metabolism of asarones. These molecules, bearing a methoxy group instead of the hydroxyl group adjacent to the propenyl side chain, have been found to be genotoxic, although they cannot directly undergo 1Ј-hydroxylation, which is the key step in bioactivation and is responsible for the genotoxic properties of many allyl compounds such as methyleugenol, safrole, or estragole (Hasheminejad and Caldwell, 1994) . Incubations of liver microsomes with synthetic 5 showed the capacity to isomerize the propenylic into an allylic side chain. However, it should be noted that the metabolic formation of 5 was observed only in incubations of ARLM or BLM.
Further metabolites were the mono-demethylated metabolites 3 and 4 and the 1Ј,2Ј-diol 7. The demethylated products 3 and 4 were found in all incubations with the highest amounts present in HLM and ARLM. Lower amounts were found in RLM and BLM.
Methylisoeugenol-1,2-epoxide (12) could not be detected. However, the formation of the diol 7 most likely originates from the intermediary formation and further reaction of 12. Metabolite 7 continuously increased and reached its highest levels after 24 h in ARLM, HLM, and BLM, whereas it was below the limit of detection in noninduced RLM.
The total recovery of metabolites together with remaining starting material was greater than 70% after the first 3 h of incubation in all types of microsomes investigated. The turnover rate of 1 was highest in ARLM and lower in HLM, BLM, and RLM. The amounts of 2 found after a 3-h incubation time-ranked unanimously as follows: RLM Ͼ HLM Ͼ BLM Ͼ ARLM.
These findings show that microsomes from human, rat, and bovine liver are able to generate a broad spectrum of phase-I metabolites when incubated with 1, a common ingredient of cosmetics and constituent of flavoring preparations in foods and beverages. However, an investigation is needed to determine whether the differences found in liver microsomes from three different species are indicative of speciesselective patterns of hepatic metabolism of 1 in intact cells or in vivo.
3Ј-Hydroxylation forming 2 was the major pathway of 1. Alcohol 2 was shown to be the precursor of the ␣,␤-unsaturated aldehyde 6. This metabolite and the 1Ј,2Ј-epoxide 12, which could not be detected but can be assumed to be a precursor of the 1Ј,2Ј-diol 7, have the reactive capacity to bind to proteins and other hepatic macromolecules. The second major reaction of 1 in bovine and Aroclor1254-induced rat liver microsomes was found to be ring hydroxylation at position 6. This reaction was not or barely detectable in microsomes from humans and noninduced rats. We were surprised to find that formation of 8, the allylic isomer of the 6-hydroxylated metabolite 5, was observed, bringing about the capability of formation of putative genotoxic secondary metabolites hydroxylated at the 1Ј position. Future studies will be aimed at investigating the actual toxic potency of these reactive metabolites and their relevance of formation.
